Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 6/20 | 0.37 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231869 | 0.87 | TAAR1 (0.41) | TAAR1TYMPHPGDKRASHINT1 | |
| SCHEMBL6231468 | 0.85 | TAAR1 (0.37) | POLBTAAR1TYMPHPGDHINT1 | |
| SCHEMBL6835146 | 0.84 | TYMP (0.45) | POLBTAAR1TYMPHPGDP2RY2 | |
| SCHEMBL8006782 | 0.84 | TAAR1 (0.39) | POLBTAAR1TYMPHPGDKRAS | |
| SCHEMBL6316021 | 0.83 | TYMP (0.39) | POLBTAAR1TYMPHPGDHINT1 | |
| SCHEMBL4339434 | 0.82 | TYMP (0.37) | POLBTAAR1TYMPHPGDKRAS | |
| SCHEMBL6229383 | 0.82 | POLB (0.38) | POLBP2RY2 | |
| SCHEMBL6831424 | 0.81 | TYMP (0.36) | POLBTAAR1TYMPHPGDKRAS | |
| SCHEMBL9294597 | 0.80 | TYMP (0.46) | POLBTAAR1TYMPHPGDP2RY2 | |
| SCHEMBL6835155 | 0.79 | TYMP (0.36) | POLBTAAR1TYMPHPGDKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | POLB 59/4885TAAR1 1797/4885TYMP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.